Ece HARMAN, Serkan AKCAY, Yankı BUKE, Hakan ER

Niacin: Does It affect 8-hydroxy-2-deoxyguanosine levels of the patients having low HDL cholesterol levels?

We aimed to determine whether niacin improve plasma HDL-cholesterol levels by decreasing 8-Hydroxydeoxyguanosıne (8-OHdG) as a biomarker of oxidative DNA damage or not. Patients (n=32) with low HDL-cholesterol levels (40 mg/dl) were included in the study. Lipoprotein profiles (total cholesterol, HDL-C, and total triglycerides) were measured in all patients. LDL-C was calculated as described by Friedewald et al. Before and after 16 week of niacin therapy serum 8-OHdG was measured. There were significant difference between pre and post treatment plasma HDL-C and 8-OHdG levels. We concluded that niacin may raise HDL-C levels. The improvement of plasma HDL-C levels may have a protective effect on endothelial dysfunction. By reducing the level of 8-OHdG, niacin may decrease DNA damage. Thus, niacin therapy may be consider as an alternative to statins or fibrates in patients in whom fail to sufficiently correct low HDL-C levels.

Keywords:

Niacin, 8-OHdG, HDL cholesterol,

PDF

___

Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol. 2004;15(6):659-65.
Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000;2(1):36-46.
Singh V, Sharma R, Kumar A, Deedwania P. Low high-density lipoprotein cholesterol: current status and future strategies for management. Vasc Health Risk Manag. 2010;29(6):979-96.
Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30(5):968-75.
Lee K, Ahn TH, Kang WC, Han SH, Choi IS, Shin EK. The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stres in patients with mild to moderate coronary artery stenosis. Korean Circ J. 2011;41(11):641-8.
Wu BJ, Chen K, Barter PJ, Rye KA. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Curr Atheroscler Rep. 2012;14(1):49-59. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-55.
Knopp RH, Retzlaff BM, Fish B, Dowdy A, Twaddell B, Nguyen T, Paramsothy P. The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. J Clin Lipidol. 2009;3(3):167
AIM-HIGH: Niacin plus Statin to Prevent Vascular Events. Accessed at http://clinicaltrials.gov/ct2/show/NCT00120289
HPS2-THRIVE: A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant. Accessed at http://clinicaltrials.gov/ct2/show/NCT00461630